靶向CD46的免疫调节抗体偶联药物FOR46(FG-3246)在转移性去势抵抗性前列腺癌患者中的Ⅰ期首次人体研究
这项Ⅰ期首次人体剂量递增/扩展研究纳入56例经≥一种雄激素信号抑制剂治疗后进展的转移性去势抵抗性前列腺癌患者,FOR46静脉给药每3周一次,起始剂量0.1 mg/kg。最大耐受剂量为按调整体重计算的2.7 mg/kg,常见≥3级不良事件为中性粒细胞减少(59%)。在疗效可评估子集(n=40)中,中位影像学无进展生存期为8.7个月,PSA50缓解率为36%(14/39),确认客观缓解率为20%(5/25)。
要点
- FOR46的最大耐受剂量为按调整体重计算的2.7 mg/kg,每3周静脉给药一次。
- 所有剂量水平最常见≥3级不良事件为中性粒细胞减少(59%),无治疗相关死亡。
- 疗效可评估子集(n=40)中位影像学无进展生存期8.7个月,PSA50缓解率36%(14/39)。
核心结论
- FOR46显示出令人鼓舞的初步临床活性,安全性可控。
- 靶向CD46可引发免疫启动效应,该效应与临床结局相关。
研究设计与样本
- Ⅰ期首次人体剂量递增/扩展研究,纳入经≥一种雄激素信号抑制剂治疗后进展的转移性去势抵抗性前列腺癌患者,共56例。
- FOR46起始剂量0.1 mg/kg,静脉给药,每3周一次。
- 主要目标为确定最大耐受剂量(MTD)。
- 采用全血质谱流式技术(飞行时间流式细胞术)表征外周免疫反应,并对经中心病理复核的前列腺癌组织进行CD46表达分析。
主要发现
- 剂量限制性毒性包括中性粒细胞减少(n=4)、发热性中性粒细胞减少(n=1)和乏力(n=1)。
- 最大耐受剂量为按调整体重计算的2.7 mg/kg。
- 所有剂量水平最常见≥3级不良事件为中性粒细胞减少(59%)、白细胞减少(27%)、淋巴细胞减少(7%)、贫血(7%)和乏力(5%)。
- 观察到1例3级发热性中性粒细胞减少事件,无治疗相关死亡。
- 疗效可评估子集(接受起始剂量≥1.2 mg/kg的腺癌患者,n=40)中位影像学无进展生存期为8.7个月(范围0.1-33.9)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: FOR46, a fully human antibody conjugated to monomethyl auristatin E, targets a tumor-selective epitope of CD46, which is overexpressed in metastatic castration-resistant prostate cancer (mCRPC). FOR46 demonstrates potent nonclinical activity in enzalutamide-resistant CRPC models. PATIENTS AND METHODS: This was a phase I, first-in-human, dose escalation/expansion study in patients with progressive mCRPC after treatment with ≥one androgen signaling inhibitors (ClinicalTrials.gov identifier: NCT03575819). The starting dose of FOR46 was 0.1 mg/kg given intravenously every 3 weeks. The primary objective was to determine the maximally tolerated dose (MTD). Whole-blood mass cytometry (cytometry by time of flight) was used to characterize peripheral immune response and CD46 expression in CRPC tissue that underwent central pathology review. RESULTS: Fifty-six patients were enrolled. Dose-limiting toxicities included neutropenia (n = 4), febrile neutropenia (n = 1), and fatigue (n = 1). The MTD was 2.7 mg/kg using adjusted body weight. The most common grade ≥3 adverse events across all dose levels were neutropenia (59%), leukopenia (27%), lymphopenia (7%), anemia (7%), and fatigue (5%). One grade 3 febrile neutropenia event was observed. There were no treatment-related deaths. In the efficacy evaluable subset (patients with adenocarcinoma treated with a starting dose ≥1.2 mg/kg, n = 40), the median radiographic progression-free survival was 8.7 months (range, 0.1-33.9). Fourteen of 39 evaluable patients (36%) achieved a PSA50 response. The confirmed objective response rate was 20% (5 of 25 RECIST-evaluable patients). The median duration of response was 7.5 months. Responders had a significantly higher on-treatment frequency of circulating effector CD8+ T cells. CONCLUSION: FOR46 demonstrated encouraging preliminary clinical activity with a manageable safety profile. Targeting CD46 elicited an immune priming effect that was associated with clinical outcomes.
引用
- Aggarwal RR, Vuky J, VanderWeele D, et al. Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2025. PMID: 40138611. doi:10.1200/JCO-24-01989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。